Neuren Pharmaceuticals revenue and financials

NEU · ASX · AUD

$22.98Change from previous close: −0.09%Absolute change: −$0.02

Close · November 16, 2026

In the fiscal year ended December 2025, Neuren Pharmaceuticals reported revenue of $64.65M (−70.18% year over year). Net income was $30.44M, a net margin of 47.1%.

Annual revenue · 2025: $64.65M
  1. $3.15M2016
  2. $631K2017
  3. $13.99M2018
  4. $495K2019
  5. $717K2020
  6. $3.2M2021
  7. $15.42M2022
  8. $231.94M2023
  9. $216.83M2024
  10. $64.65M2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
−70.18%
2025 vs 2024
Net income growth
−78.57%
2025 vs 2024
Net margin
47.1%
2024: 65.5%

How Neuren Pharmaceuticals is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of AUD; per-share values in AUD; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue64.621723215.43.20.70.514.00.63.2
Cost of revenue36.433.026.812.79.57.89.96.15.113.3
Gross profit28.31842052.7-6.3-7.0-9.47.9-4.5-10.2
Selling, general and administrative6.24.75.93.41.91.81.72.11.61.8
Research and development36.433.026.812.7——————
Operating income22.0179199-0.7-8.2-8.8-11.15.8-6.1-12.0
EBIT22.0179199-0.7-8.2-8.8-11.15.8-6.1-12.0
EBITDA22.1179199-0.7-8.2-8.8-11.15.9-6.0-11.9
Pre-tax income38.91832050.2-7.8-9.2-10.83.13.3-12.0
Income tax8.540.948.10.0——————
Net income30.41421570.2-7.8-9.2-10.83.13.3-12.0
Net income to common shareholders30.41421570.2-7.8-9.2-10.83.13.3-12.0
Basic EPS0.241.111.240.00-0.07-0.09-0.110.030.04-0.14
Diluted EPS0.231.091.200.00-0.07-0.09-0.110.030.03-0.14
Average shares (basic)12812812712611810710099.092.084.7
Average shares (diluted)13113113112911910710099.893.084.7

Companies in the group: same industry, similar size